Los Angeles-based Cedars-Sinai will receive up to $5,054,235 from the federal ARPA-H CATALYST program to develop an AI platform designed to predict drug toxicity before clinical trials begin.
The platform will use AI to analyze “patient avatars” — organ-on-chip systems derived from human stem cells — to forecast how medications may affect human organs over time. The goal is to reduce clinical trial failures caused by adverse drug reactions, which account for more than 30% of trial shutdowns, according to a Jan. 13 news release from the health system.
The AI system is powered by millions of de-identified data points from Cedars-Sinai’s EHRs and incorporates patient-specific factors such as age, comorbidities and medication use to model evolving drug risk.
